+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bivalirudin Market by End User (Ambulatory Surgical Centers, Hospitals), Formulation (Lyophilized Powder, Prefilled Syringes), Application, Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Bivalirudin Market by End User (Ambulatory Surgical Centers, Hospitals), Formulation (Lyophilized Powder, Prefilled Syringes), Application, Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Bivalirudin Market by End User (Ambulatory Surgical Centers, Hospitals), Formulation (Lyophilized Powder, Prefilled Syringes), Application, Route Of Administration, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083118
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Bivalirudin Market is positioned for substantial evolution as healthcare systems seek advanced anticoagulant solutions suited for increasingly complex clinical settings. Senior executives evaluating next-generation therapies will find actionable insights in this comprehensive resource.

Market Snapshot: Bivalirudin Market Growth and Trends

The global bivalirudin market grew from USD 1.31 billion in 2024 to USD 1.39 billion in 2025. Projected at a CAGR of 6.16%, market revenues are set to reach USD 1.87 billion by 2030. This upward trajectory reflects the shift toward more precise and predictable anticoagulation therapies across a broadening array of clinical pathways, especially as healthcare providers respond to rising patient complexity and demand for reliability. The expansion is also fuelled by heightened adoption in acute care settings and continual innovation in administration and formulation.

Bivalirudin Market Scope & Segmentation

The scope of this report covers granular analysis along the following axes:

  • End Users: Includes ambulatory surgical centers (both hospital owned and standalone) and hospitals (categorized as private or public).
  • Formulations: Offers lyophilized powder for direct use or reconstitution, and prefilled syringes with both glass and plastic barrel options.
  • Applications: Focus on myocardial infarction (NSTEMI, STEMI), percutaneous coronary intervention (elective and emergency), and unstable angina.
  • Routes of Administration: Intravenous bolus and intravenous infusion types, with methods such as continuous or intermittent infusion.
  • Distribution Channels: Hospital pharmacies (in-house and third-party managed) and retail pharmacies (chain and independent, including specialty compounding).
  • Geographic Coverage: Comprehensive regional analysis across Americas (U.S. with state breakdown, Canada, Mexico, Brazil, Argentina), Europe Middle East & Africa (with focus countries such as United Kingdom, Germany, UAE, and more), and Asia-Pacific (including China, India, Japan, Australia, and other key markets).
  • Company Coverage: In-depth trend analysis for key market players including Fresenius Kabi AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Sandoz International GmbH, Baxter International Inc., and B. Braun Melsungen AG.

Key Takeaways for Senior Decision-Makers

  • Bivalirudin’s unique pharmacological profile continues to drive preference in percutaneous interventions and settings where clinical risk stratification is critical.
  • Operational protocols are standardizing to facilitate streamlined drug preparation and administration, minimizing medication errors and improving process efficiency.
  • The adoption of ready-to-use technologies and automated infusion systems is improving dosing accuracy and facilitating interdepartmental coordination.
  • Regional expansion strategies hinge on adapting to varied reimbursement environments and optimizing supply networks to manage procurement risks.
  • Strategic collaborations are emerging between pharmaceutical firms and device manufacturers, integrating digital tools like dosage calculators and remote monitoring for tailored patient care.

Tariff Impact: Navigating Supply Chain and Cost Structures

Newly introduced United States tariffs on select pharmaceutical inputs in 2025 have influenced bivalirudin’s supply chain and cost base. Manufacturers are reassessing sourcing strategies, renegotiating contracts, and considering increased domestic production to mitigate supply risks. Regulatory engagement is intensifying as industry stakeholders seek to maintain continuity and meet stringent quality requirements in light of these dynamic trade policies.

Methodology & Data Sources

This report employs a blended research approach, integrating direct interviews with clinicians, pharmacists, supply chain managers, and administrative stakeholders. These insights are triangulated with public databases, regulatory records, industry consortium reports, and peer-reviewed studies to ensure robust trend validation and actionable market intelligence.

Bivalirudin Market: Why This Report Matters

  • Delivers evidence-based intelligence for C-suite executives to inform product strategy and network optimization amid changing clinical standards and regulatory policies.
  • Supports alignment of procurement, supply management, and therapeutic protocols for improved operational performance and patient outcomes.
  • Enables market entry and expansion planning with detailed segmentation, competitive intelligence, and risk mitigation strategies tailored to regional nuances.

Conclusion

Bivalirudin’s expanding role in evidence-driven care makes strategic planning essential for organizations targeting growth and operational excellence. Executives who leverage robust market segmentation, supply chain agility, and integrated delivery systems will be best placed for long-term success in global anticoagulation markets.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Analysis of price erosion and profitability impact following bivalirudin patent expiry and generic competitor entry
5.2. Evaluation of clinical guideline updates favoring bivalirudin use in high bleeding risk percutaneous interventions
5.3. Assessment of cost-effectiveness in real-world hospital protocols comparing bivalirudin with heparin plus glycoprotein inhibitors
5.4. Impact of generic direct thrombin inhibitor competitors on branded bivalirudin market dynamics across key regions
5.5. Integration of electronic health record decision support for personalized bivalirudin dosing to reduce bleeding complications
5.6. Analysis of evolving reimbursement policies and value-based contracting affecting hospital adoption rates of bivalirudin therapy
5.7. Trends in radial access percutaneous coronary interventions driving increased bivalirudin utilization in cardiology suites
5.8. Opportunities in emerging Asian and Latin American markets for bivalirudin with expanding interventional cardiology infrastructure
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bivalirudin Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.2.1. Hospital Owned Ambulatory Surgical Centers
8.2.2. Standalone Ambulatory Surgical Centers
8.3. Hospitals
8.3.1. Private Hospitals
8.3.2. Public Hospitals
9. Bivalirudin Market, by Formulation
9.1. Introduction
9.2. Lyophilized Powder
9.2.1. Powder For Direct Use
9.2.2. Powder For Reconstitution
9.3. Prefilled Syringes
9.3.1. Glass Barrel
9.3.2. Plastic Barrel
10. Bivalirudin Market, by Application
10.1. Introduction
10.2. Myocardial Infarction
10.2.1. NSTEMI
10.2.2. STEMI
10.3. Percutaneous Coronary Intervention
10.3.1. Elective PCI
10.3.2. Emergency PCI
10.4. Unstable Angina
11. Bivalirudin Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous Bolus
11.3. Intravenous Infusion
11.3.1. Continuous Infusion
11.3.2. Intermittent Infusion
12. Bivalirudin Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.2.1. In-House Pharmacy
12.2.2. Third-Party Managed Pharmacy
12.3. Retail Pharmacy
12.3.1. Chain Retail Pharmacy
12.3.2. Independent Retail Pharmacy
13. Americas Bivalirudin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Bivalirudin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Bivalirudin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Fresenius Kabi AG
16.3.2. Pfizer Inc.
16.3.3. Teva Pharmaceutical Industries Ltd.
16.3.4. Viatris Inc.
16.3.5. Apotex Inc.
16.3.6. Sandoz International GmbH
16.3.7. Baxter International Inc.
16.3.8. B. Braun Melsungen AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIVALIRUDIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. BIVALIRUDIN MARKET: RESEARCHAI
FIGURE 26. BIVALIRUDIN MARKET: RESEARCHSTATISTICS
FIGURE 27. BIVALIRUDIN MARKET: RESEARCHCONTACTS
FIGURE 28. BIVALIRUDIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL OWNED AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL OWNED AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY STANDALONE AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY STANDALONE AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BIVALIRUDIN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BIVALIRUDIN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BIVALIRUDIN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BIVALIRUDIN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER FOR DIRECT USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER FOR DIRECT USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER FOR RECONSTITUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER FOR RECONSTITUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BIVALIRUDIN MARKET SIZE, BY GLASS BARREL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BIVALIRUDIN MARKET SIZE, BY GLASS BARREL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BIVALIRUDIN MARKET SIZE, BY PLASTIC BARREL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BIVALIRUDIN MARKET SIZE, BY PLASTIC BARREL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BIVALIRUDIN MARKET SIZE, BY NSTEMI, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BIVALIRUDIN MARKET SIZE, BY NSTEMI, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BIVALIRUDIN MARKET SIZE, BY STEMI, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BIVALIRUDIN MARKET SIZE, BY STEMI, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BIVALIRUDIN MARKET SIZE, BY ELECTIVE PCI, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BIVALIRUDIN MARKET SIZE, BY ELECTIVE PCI, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BIVALIRUDIN MARKET SIZE, BY EMERGENCY PCI, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BIVALIRUDIN MARKET SIZE, BY EMERGENCY PCI, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BIVALIRUDIN MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BIVALIRUDIN MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS BOLUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS BOLUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BIVALIRUDIN MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BIVALIRUDIN MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BIVALIRUDIN MARKET SIZE, BY IN-HOUSE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BIVALIRUDIN MARKET SIZE, BY IN-HOUSE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BIVALIRUDIN MARKET SIZE, BY THIRD-PARTY MANAGED PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BIVALIRUDIN MARKET SIZE, BY THIRD-PARTY MANAGED PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BIVALIRUDIN MARKET SIZE, BY CHAIN RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BIVALIRUDIN MARKET SIZE, BY CHAIN RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL BIVALIRUDIN MARKET SIZE, BY INDEPENDENT RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL BIVALIRUDIN MARKET SIZE, BY INDEPENDENT RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 155. CANADA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. CANADA BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. CANADA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 158. CANADA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 159. CANADA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 160. CANADA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 161. CANADA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 162. CANADA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 163. CANADA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 164. CANADA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 165. CANADA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 166. CANADA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 167. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. CANADA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 170. CANADA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 171. CANADA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 172. CANADA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 173. CANADA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. CANADA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. CANADA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 176. CANADA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 177. CANADA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. CANADA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. CANADA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 180. CANADA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 181. CANADA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 182. CANADA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 183. MEXICO BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. MEXICO BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. MEXICO BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 186. MEXICO BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 187. MEXICO BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 188. MEXICO BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 189. MEXICO BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 191. MEXICO BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 192. MEXICO BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 193. MEXICO BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 194. MEXICO BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 195. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. MEXICO BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 198. MEXICO BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 199. MEXICO BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 200. MEXICO BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 201. MEXICO BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. MEXICO BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. MEXICO BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 204. MEXICO BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 205. MEXICO BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. MEXICO BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. MEXICO BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 208. MEXICO BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 209. MEXICO BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 210. MEXICO BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 318. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2025-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 322. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 324. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 325. GERMANY BIVALIRUDIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. GERMANY BIVALIRUDIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. GERMANY BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 328. GERMANY BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 329. GERMANY BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 330. GERMANY BIVALIRUDIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 331. GERMANY BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 332. GERMANY BIVALIRUDIN MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 333. GERMANY BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 334. GERMANY BIVALIRUDIN MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 335. GERMANY BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 336. GERMANY BIVALIRUDIN MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 337. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 338. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 339. GERMANY BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2018-2024 (USD MILLION)
TABLE 340. GERMANY BIVALIRUDIN MARKET SIZE, BY MYOCARDIAL INFARCTION, 2025-2030 (USD MILLION)
TABLE 341. GERMANY BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
TABLE 342. GERMANY BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2030 (USD MILLION)
TABLE 343. GERMANY BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 344. GERMANY BIVALIRUDIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 345. GERMANY BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION, 2018-2024 (USD MILLION)
TABLE 346. GERMANY BIVALIRUDIN MARKET SIZE, BY INTRAVENOUS INFUSION,

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Bivalirudin market report include:
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Sandoz International GmbH
  • Baxter International Inc.
  • B. Braun Melsungen AG

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.87 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Bivalirudin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Bivalirudin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 85 Pages
  • Global
From
Bivalirudin (CAS 128270-60-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Bivalirudin (CAS 128270-60-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Heparin Induced Thrombocytopenia (HIT) Epidemiology Forecast 2025-2034 - Product Image

Heparin Induced Thrombocytopenia (HIT) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From

About the Market

Bivalirudin is a cardiovascular drug used to treat and prevent blood clots in patients undergoing coronary angioplasty and other procedures. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, an enzyme involved in the formation of blood clots. Bivalirudin is administered intravenously and is often used in combination with other anticoagulants. It is also used to treat patients with unstable angina and non-ST-segment elevation myocardial infarction. Bivalirudin is a relatively new drug, having been approved by the U.S. Food and Drug Administration in 2000. It has become increasingly popular in recent years due to its efficacy and safety profile. It is also cost-effective compared to other anticoagulants, making it an attractive option for healthcare providers. Several companies are involved in the bivalirudin market, including AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Merck, and Sanofi. These companies manufacture and market bivalirudin-based products, such as Angiomax and Refludan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.